January 22, 2016
The Japanese Society of Medical Oncology issued on January 21 a statement calling for the proper use of Ono Pharmaceutical’s anti-PD-1 antibody Opdivo (nivolumab) after the drug obtained a lung cancer indication in December. The society in the statement noted...read more